feb 12, 2019: 2 p.m. - 3 p.m.
Shubert Complex - 6th Floor
After years of sparse development of new antimicrobials, R&D incentive initiatives such as CARB-X have helped grow late-stage pipelines and new approvals. Unfortunately, difficult commercialization experiences of leaders in this space threaten to derail the momentum of the sector. In response, the FDA has proposed the health care system consider a subscription model for the purchase of antibiotics by hospitals in an effort to increase the reliability of a return on investment in new antibiotics and avoid high-volume prescribing practices that would accelerate antimicrobial resistance. This session will include policy, antimicrobial developer, and investor perspectives on this issue to discuss the opportunities and challenges of business model changes and what it will take to avoid a crisis described by the World Health Organization as a %u201Cpost-antibiotic era where common infections and minor injuries can once again kill.%u201D
Moderator: Gregory Frank, PhD, Director, Infectious Disease Policy, Biotechnology Innovation Organization (BIO)